HtrA serine proteases as potential therapeutic targets in cancer

Current Cancer Drug Targets

Volumn 9, Issue 4, 2009, Pages 451-468

  Chien, Jeremy ^c   Campioni, Mara ^a   Shridhar, Viji ^c   Baldi, Alfonso ^b  

^a SECOND UNIVERSITY OF NAPLES   (Italy)

^b Pathology Section   (Italy)

^c Mayo Clinic   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 AMINO 6 BROMO 4 (1 CYANO 2 ETHOXY 2 OXOETHYL) 4H CHROMENE 3 CARBOXYLIC ACID ETHYL ESTER; 4 [4 (4' CHLORO 2 BIPHENYLYLMETHYL) 1 PIPERAZINYL] N [4 [3 DIMETHYLAMINO 1 (PHENYLTHIOMETHYL)PROPYLAMINO] 3 NITROBENZENESULFONYL]BENZAMIDE; 5 AZA 2' DEOXYCYTIDINE; ANTISENSE OLIGONUCLEOTIDE; AZACITIDINE; BORTEZOMIB; CISPLATIN; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR; ETOPOSIDE; EVEROLIMUS; FLAVOPIRIDOL; INHIBITOR OF APOPTOSIS PROTEIN; INHIBITOR OF APOPTOSIS PROTEIN ANTAGONIST; ISPINESIB; LBW 242; OBLIMERSEN; PACLITAXEL; PANOBINOSTAT; RAPAMYCIN; RO 317453; SERINE PROTEINASE; SERINE PROTEINASE HTRA; SERINE PROTEINASE HTRA1; SERINE PROTEINASE HTRA3; SERINE PROTEINASE HTRA4; SERINE PROTEINASE OMI; TANESPIMYCIN; TPI 1396912; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; TWX 024; UNCLASSIFIED DRUG; UNINDEXED DRUG; VASCULOTROPIN RECEPTOR;

ALLELE; APOPTOSIS; ASTROCYTOMA; BRAIN TUMOR; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER THERAPY; CARCINOGENESIS; CYTOTOXICITY; DISEASE SEVERITY; DRUG INHIBITION; DRUG MECHANISM; DRUG TARGETING; EPIGENETICS; GLIOBLASTOMA; HUMAN; LUNG ADENOCARCINOMA; MEDULLOBLASTOMA; MESOTHELIOMA; NONHUMAN; NUCLEOTIDE SEQUENCE; OLIGODENDROGLIOMA; OVARY CANCER; PROSTATE CARCINOMA; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN TARGETING; REVIEW; SQUAMOUS CELL CARCINOMA;

ANTINEOPLASTIC AGENTS; APOPTOSIS; APOPTOSIS REGULATORY PROTEINS; DRUG DELIVERY SYSTEMS; EPIGENESIS, GENETIC; GENE EXPRESSION; HUMANS; MODELS, BIOLOGICAL; NEOPLASMS; SEQUENCE ANALYSIS, DNA; SERINE ENDOPEPTIDASES;

EID: 67649305413     PISSN: 15680096     EISSN: None     Source Type: Journal    
DOI: 10.2174/156800909788486704     Document Type: Review

References (158)

1. Fulda, S.; Debatin, K. M. Extrinsic versus intrinsic apoptosis pathways in anticancer chemotherapy. Oncogene 2006, 25(34), 4798-4811. (Pubitemid 44187627)
2. Meiler, J.; Schuler, M. Therapeutic targeting of apoptotic pathways in cancer. Curr. Drug Targets 2006, 7(10), 1361-1369. (Pubitemid 44509700)
3. Nelson, E. C.; Cambio, A. J.; Yang, J. C.; Lara, P. N. Jr.; Evans, C. P. Biologic agents as adjunctive therapy for prostate cancer: a rationale for use with androgen deprivation. Nat. Clin. Pract. Urol. 2007, 4(2), 82-94. (Pubitemid 46252235)
4. Kaufmann, S. H.; Vaux, D. L. Alterations in the apoptotic machinery and their potential role in anticancer drug resistance. Oncogene 2003, 22(47), 7414-7430. (Pubitemid 37487167)
5. Danial, N. N.; Korsmeyer, S. J. Cell death: critical control points. Cell 2004, 116(2), 205-219. (Pubitemid 38167313)
6. Brown, J. M.; Wouters, B. G. Apoptosis: mediator or mode of cell killing by anticancer agents? Drug Resist. Updat. 2001, 4(2), 135-136. (Pubitemid 32619572)
7. Brown, J. M.; Wouters, B. G. Apoptosis, p53, and tumor cell sensitivity to anticancer agents. Cancer Res. 1999, 59(7), 1391-1399. (Pubitemid 29160097)
8. Schmitt, C. A.; Lowe, S. W. Apoptosis is critical for drug response in vivo. Drug Resist. Updat 2001, 4(2), 132-134. (Pubitemid 32619571)
9. Schmitt, C. A.; Lowe, S. W. Apoptosis and chemoresistance in transgenic cancer models. J. Mol. Med. 2002, 80(3), 137-146. (Pubitemid 34230634)
10. Reed, J. C. Dysregulation of Apoptosis in Cancer. J. Clin. Oncol. 1999, 17(9), 2941-2953. (Pubitemid 29415256)
11. Hanahan, D.; Weinberg, R. A. The hallmarks of cancer. Cell 2000, 100(1), 57-70. (Pubitemid 30046295)
12. Kaufmann, S. H.; Hengartner, M. O. Programmed cell death: alive and well in the new millennium. Trends Cell Biol. 2001, 11(12), 526-534. (Pubitemid 33079147)
13. Jiang, N.; Wang, X.; Yang, Y.; Dai, W. Advances in mitotic inhibitors for cancer treatment. Mini Rev. Med. Chem. 2006, 6(8), 885-895. (Pubitemid 44194376)
14. Epstein, R. J. Drug-induced DNA damage and tumor chemosensitivity. J. Clin. Oncol. 1990, 8(12), 2062-2084.
15. Schmidt, M.; Bastians, H. Mitotic drug targets and the development of novel anti-mitotic anticancer drugs. Drug Resist. Updat 2007, 10(4-5), 162-181. (Pubitemid 47449762)
16. Tallmann, M. S. Curative therapeutic approaches to APL. Ann. Hematol. 2004, 83(1), 81-82.
17. Brueggemeier, R. W. Update on the use of aromatase inhibitors in breast cancer. Expert Opin. Pharmacother. 2006, 7(14), 1919-1930. (Pubitemid 44489366)
18. Ramirez, M. L.; Keane, T. E.; Evans, C. P. Managing prostate cancer: the role of hormone therapy. Can. J. Urol. 2007, 14 (1), 10-18.
19. O'Connor, M. J.; Martin, N. M.; Smith, G. C. Targeted cancer therapies based on the inhibition of DNA strand break repair. Oncogene 2007, 26(56), 7816-7824. (Pubitemid 350242461)
20. Leary, A.; Johnston, S. R. Small molecule signal transduction inhibitors for the treatment of solid tumors. Cancer Invest. 2007, 25(5), 347-365. (Pubitemid 47185077)
21. Rowinsky, E. K., Targeted induction of apoptosis in cancer management: the emerging role of tumor necrosis factor-related apoptosis-inducing ligand receptor activating agents. J. Clin. Oncol. 2005, 23(36), 9394-9407. (Pubitemid 46260199)
22. Shapiro, G. I. Cyclin-dependent kinase pathways as targets for cancer treatment. J. Clin. Oncol. 2006, 24(11), 1770-1783. (Pubitemid 46628473)
23. O'Connor, O. A. Targeting histones and proteasomes: new strategies for the treatment of lymphoma. J. Clin. Oncol. 2005, 23(26), 6429-6436. (Pubitemid 46218854)
24. Adjei, A. A.; Hidalgo, M. Intracellular signal transduction pathway proteins as targets for cancer therapy. J. Clin. Oncol. 2005, 23(23), 5386-5403. (Pubitemid 46206992)
25. Petricoin, E. F. 3rd; Bichsel, V. E.; Calvert, V. S.; Espina, V.; Winters, M.; Young, L.; Belluco, C.; Trock, B. J.; Lippman, M.; Fishman, D. A.; Sgroi, D. C.; Munson, P. J.; Esserman, L. J.; Liotta, L. A. Mapping molecular networks using proteomics: a vision for patient-tailored combination therapy. J. Clin. Oncol. 2005, 23(15), 3614-3621.
26. Dy, G. K.; Adjei, A. A. Novel targets for lung cancer therapy: part I. J. Clin. Oncol. 2002, 20(12), 2881-2894. (Pubitemid 34651518)
27. Pennati, M.; Folini, M.; Zaffaroni, N. Targeting survivin in cancer therapy. Expert Opin. Ther. Targets 2008, 12(4), 463-476. (Pubitemid 351551639)
28. Dy, G. K.; Haluska, P.; Adjei, A. A. Novel pharmacological agents in clinical development for solid tumours. Expert Opin. Investig. Drugs 2001, 10(12), 2059-2088.
29. Baird, R. D.; Kaye, S. B. Drug resistance reversal - are we getting closer? Eur. J. Cancer 2003, 39(17), 2450-2461. (Pubitemid 37340159)
30. Agarwal, R.; Linch, M.; Kaye, S. B. Novel therapeutic agents in ovarian cancer. Eur. J. Surg. Oncol. 2006, 32(8), 875-886. (Pubitemid 44469301)
31. Vannucchi, S.; Chiantore, M. V.; Mangino, G.; Percario, Z. A.; Affabris. E.; Fiorucci, G.; Romeo, G. Perspectives in biomolecular therapeutic intervention in cancer: from the early to the new strategies with type I interferons. Curr. Med. Chem. 2007, 14(6), 667-679. (Pubitemid 46477719)
32. Hutson, T. E.; Figlin, R. A. Evolving role of novel targeted agents in renal cell carcinoma. Oncology 2007, 21(10), 1175-1190.
33. Glaser, K. B. HDAC inhibitors: Clinical update and mechanism-based potential. Biochem. Pharmacol. 2007, 74(5), 659-671. (Pubitemid 47096639)
34. McDonald, C. J.; Erlichman, C.; Ingle, J. N.; Rosales, G. A.; Allen, C.; Greiner, S. M.; Harvey, M. E.; Zollman, P. J.; Russell, S. J.; Galanis, E. A measles virus vaccine strain derivative as a novel oncolytic agent against breast cancer. Breast Cancer Res. Treat. 2006, 99(2), 177-184. (Pubitemid 44268265)
35. Allen, C., Paraskevakou, G.; Liu, C.; Iankov, I. D.; Msaouel, P.; Zollman, P.; Myers, R.; Peng, K. W.; Russell, S. J.; Galanis, E. Oncolytic measles virus strains in the treatment of gliomas. Expert. Opin. Biol. Ther. 2008, 8(2), 213-220. (Pubitemid 351233714)
36. Fulda, S. Modulation of TRAIL-induced apoptosis by HDAC inhibitors. Curr. Cancer Drug Targets 2008, 8(2), 132-140. (Pubitemid 351347249)
37. Zhou, X. C.; Dowdy, S. C.; Podratz, K. C.; Jiang, S. W. Epigenetic considerations for endometrial cancer prevention, diagnosis and treatment. Gynecol. Oncol. 2007, 107(1), 143-153. (Pubitemid 47464554)
38. Swaminathan, V.; Reddy, B. A.; Ruthrotha Selvi, B.; Sukanya, M. S.; Kundu, T. K. Small molecule modulators in epigenetics: implications in gene expression and therapeutics. Subcell. Biochem. 2007, 41, 397-428.
39. Fandy, T. E.; Carraway, H.; Gore, S. D. DNA demethylating agents and histone deacetylase inhibitors in hematologic malignancies. Cancer J. 2007, 13(1), 40-48.
40. Galm, O.; Herman, J. G.; Baylin, S. B. The fundamental role of epigenetics in hematopoietic malignancies. Blood Rev. 2006, 20(1), 1-13. (Pubitemid 43106714)
41. Sun, Q.; Brewer, N.; Dunham, K.; Chen, L.; Bao, L.; Burton, R.; Lucas, K. G. Interferon-gamma expressing EBV LMP2A-specific T cells for cellular immunotherapy. Cell. Immunol. 2007, 246(2), 81-91. (Pubitemid 47307330)
42. Adams, J. M.; Cory, S. Bcl-2-regulated apoptosis: mechanism and therapeutic potential. Curr. Opin. Immunol. 2007, 19(5), 488-496. (Pubitemid 47487452)
43. Eberle, J.; Kurbanov, B. M.; Hossini, A. M.; Trefzer, U.; Fecker, L. F. Overcoming apoptosis deficiency of melanoma-hope for new therapeutic approaches. Drug Resist. Updat. 2007, 10(6), 218-234. (Pubitemid 351163147)
44. Mitsiades, C. S.; Poulaki, V.; McMullan, C.; Negri, J.; Fanourakis, G.; Goudopoulou, A.; Richon, V. M.; Marks, P. A.; Mitsiades, N. Novel histone deacetylase inhibitors in the treatment of thyroid cancer. Clin. Cancer Res. 2005, 11(10), 3958-3965. (Pubitemid 40685618)
45. Fesik, S. W. Promoting apoptosis as a strategy for cancer drug discovery. Nat. Rev. Cancer 2005, 5(11), 876-885. (Pubitemid 41746032)
46. Dai, Y.; Grant, S. Targeting multiple arms of the apoptotic regulatory machinery. Cancer Res. 2007, 67(7), 2908-2911. (Pubitemid 46724822)
47. Reed, J. C.; Pellecchia, M. Apoptosis-based therapies for hematologic malignancies. Blood 2005, 106(2), 408-418. (Pubitemid 40981231)
48. Walensky, L. D.; Kung, A. L.; Escher, I.; Malia, T. J.; Barbuto, S.; Wright, R. D.; Wagner, G.; Verdine, G. L.; Korsmeyer, S. J. Activation of apoptosis in vivo by a hydrocarbon-stapled BH3 helix. Science 2004, 305(5689), 1466-1470. (Pubitemid 39167667)
49. Oltersdorf, T.; Elmore, S. W.; Shoemaker, A. R.; Armstrong, R. C.; Augeri, D. J.; Belli, B. A.; Bruncko, M.; Deckwerth, T. L.; Dinges, J.; Hajduk, P. J.; Joseph, M. K.; Kitada, S.; Korsmeyer, S. J.; Kunzer, A. R.; Letai, A.; Li, C.; Mitten, M. J.; Nettesheim, D. G.; Ng, S.; Nimmer, P. M.; O'Connor, J. M.; Oleksijew, A.; Petros, A. M.; Reed, J. C.; Shen, W.; Tahir, S. K.; Thompson, C. B.; Tomaselli, K. J.; Wang, B.; Wendt, M. D.; Zhang, H.; Fesik, S. W.; Rosenberg, S. H. An inhibitor of Bcl-2 family proteins induces regression of solid tumours. Nature 2005, 435(7042), 677-681. (Pubitemid 40825512)
50. Altieri, D. C. Survivin, cancer networks and pathway-directed drug discovery. Nat. Rev. Cancer 2008, 8(1), 61-70.
51. Tamm, I.; Kornblau, S. M.; Segall, H.; Krajewski, S.; Welsh, K.; Kitada, S.; Scudiero, D. A.; Tudor, G.; Qui, Y. H.; Monks, A.; Andreeff, M.; Reed, J. C. Expression and prognostic significance of IAP-family genes in human cancers and myeloid leukemias. Clin. Cancer Res. 2000, 6(5), 1796-1803. (Pubitemid 30305074)
52. Vucic, D.; Fairbrother, W. J. The inhibitor of apoptosis proteins as therapeutic targets in cancer. Clin. Cancer Res. 2007, 13(20), 5995-6000. (Pubitemid 350075054)
53. Jaattela, M. Multiple cell death pathways as regulators of tumour initiation and progression. Oncogene 2004, 23(16), 2746-2756. (Pubitemid 38638838)
54. Okada, H.; Mak, T. W. Pathways of apoptotic and non-apoptotic death in tumour cells. Nat. Rev. Cancer 2004, 4(8), 592-603. (Pubitemid 39025054)
55. Leist, M.; Jaattela, M. Four deaths and a funeral: from caspases to alternative mechanisms. Nat. Rev. Mol. Cell. Biol. 2001, 2(8), 589-598. (Pubitemid 33674010)
56. Moretti, L.; Yang, E. S.; Kim, K. W.; Lu, B. Autophagy signaling in cancer and its potential as novel target to improve anticancer therapy. Drug Resist. Updat. 2007, 10(4-5), 135-143. (Pubitemid 47454724)
57. O'Connell, A. R.; Holohan, C.; Torriglia, A.; Lee, B. W.; Stenson-Cox, C. Characterization of a serine protease-mediated cell death program activated in human leukemia cells. Exp. Cell Res. 2006, 312(1), 27-39. (Pubitemid 41668589)
58. O'Connell, A. R.; Lee, B. W.; Stenson-Cox, C. Caspase-dependant activation of chymotrypsin-like proteases mediates nuclear events during Jurkat T cell apoptosis. Biochem. Biophys. Res. Commun. 2006, 345(2), 608-616. (Pubitemid 43776990)
59. Moffitt, K. L.; Martin, S. L.; Walker, B. The emerging role of serine proteases in apoptosis. Biochem. Soc. Trans. 2007, 35(Pt 3), 559-560. (Pubitemid 46975075)
60. de Bruin, E. C.; Meersma, D,; de Wilde, J.; den Otter, I.; Schipper, E. M.; Medema, J. P.; Peltenburg, L. T. A serine protease is involved in the initiation of DNA damage-induced apoptosis. Cell Death Differ. 2003, 10(10), 1204-1212. (Pubitemid 37258585)
61. Cilenti, L.; Kyriazis, G. A.; Soundarapandian, M. M.; Stratico, V.; Yerkes, A.; Park, K. M.; Sheridan, A. M.; Alnemri, E. S.; Bonventre, J. V.; Zervos, A. S. Omi/HtrA2 protease mediates cisplatin-induced cell death in renal cells. Am. J. Physiol. Renal. Physiol. 2005, 288(2), 371-379.
62. Suzuki, Y.; Imai, Y.; Nakayama, H.; Takahashi, K.; Takio, K.; Takahashi, R. A serine protease, HtrA2, is released from the mitochondria and interacts with XIAP, inducing cell death. Mol. Cell. 2001, 8(3), 613-621. (Pubitemid 32946938)
63. Verhagen, A. M.; Silke, J.; Ekert, P. G.; Pakusch, M.; Kaufmann, H; Connolly, L. M.; Day, C. L.; Tikoo, A.; Burke, R.; Wrobel, C.; Moritz, R. L.; Simpson, R. J.; Vaux, D. L. HtrA2 promotes cell death through its serine protease activity and its ability to antagonize inhibitor of apoptosis proteins. J. Biol. Chem. 2002, 277(1), 445-454. (Pubitemid 34952078)
64. Chien, J.; Aletti. G.; Baldi, A.; Catalano, V.; Muretto, P; Keeney, G. L.; Kalli, K. R.; Staub, J.; Ehrmann, M.; Cliby, W. A.; Lee, Y. K.; Bible, K. C.; Hartmann, L. C.; Kaufmann, S. H.; Shridhar, V. Serine protease HtrA1 modulates chemotherapy-induced cytotoxicity. J. Clin. Invest. 2006, 116(7), 1994-2004. (Pubitemid 44033323)
65. Lipinska, B.; Sharma, S.; Georgopoulos, C. Sequence analysis and regulation of the htrA gene of Escherichia coli: a sigma 32-independent mechanism of heat-inducible transcription. Nucleic Acids Res. 1988, 16(21), 10053-10067. (Pubitemid 18264971)
66. Strauch, K. L.; Beckwith, J. An Escherichia coli mutation preventing degradation of abnormal periplasmic proteins. Proc. Natl. Acad. Sci. USA 1988, 85(5), 1576-1580.
67. Pallen, M. J.; Wren, B. W. The HtrA family of serine proteases. Mol. Microbiol. 1997, 26(2), 209-221. (Pubitemid 27483672)
68. Spiess, C.; Beil, A.; Ehrmann, M. A temperature-dependent switch from chaperone to protease in a widely conserved heat shock protein. Cell 1999, 97(3), 339-347. (Pubitemid 29214590)
69. Hu, S. I.; Carozza, M.; Klein, M.; Nantermet, P.; Luk, D.; Crowl, R. M. Human HtrA, an evolutionarily conserved serine protease identified as a differentially expressed gene product in osteoarthritic cartilage. J. Biol. Chem. 1998, 273(51), 34406-34412. (Pubitemid 29008919)
70. Zumbrunn, J.; Trueb, B. Primary structure of a putative serine protease specific for IGF- binding proteins. FEBS Lett. 1996, 398(2-3), 187-192. (Pubitemid 26414307)
71. Faccio, L.; Fusco, C.; Chen, A.; Martinotti, S.; Bonventre, J. V.; Zervos, A. S. Characterization of a novel human serine protease that has extensive homology to bacterial heat shock endoprotease HtrA and is regulated by kidney ischemia. J. Biol. Chem. 2000, 275(4), 2581-2588. (Pubitemid 30082024)
72. Gray, C. W.; Ward, R. V.; Karran, E.; Turconi, S.; Rowles, A; Viglienghi, D.; Southan, C.; Barton, A.; Fantom, K. G.; West, A.; Savopoulos, J.; Hassan, N. J.; Clinkenbeard, H.; Hanning, C.; Amegadzie, B.; Davis, J. B.; Dingwall, C.; Livi, G. P.; Creasy, C. L. Characterization of human HtrA2, a novel serine protease involved in the mammalian cellular stress response. Eur. J. Biochem. 2000, 267(18), 5699-5710. (Pubitemid 30706937)
73. Nie, G. Y.; Hampton, A.; Li, Y.; Findlay, J. K.; Salamonsen, L. A. Identification and cloning of two isoforms of human high-temperature requirement factor A3 (HtrA3), characterization of its genomic structure and comparison of its tissue distribution with HtrA1 and HtrA2. Biochem. J. 2003, 371(1), 39-48. (Pubitemid 36458077)
74. Oka, C.; Tsujimoto, R.; Kajikawa, M.; Koshiba-Takeuchi, K.; Ina, J.; Yano, M.; Tsuchiya, A.; Ueta, Y.; Soma, A.; Kanda, H.; Matsumoto, M.; Kawaichi, M. HtrA1 serine protease inhibits signaling mediated by Tgfbeta family proteins. Development 2004, 131(5), 1041-1053. (Pubitemid 38380458)
75. Clausen, T.; Southan, C.; Ehrmann, M. The HtrA family of proteases: implications for protein composition and cell fate. Mol. Cell. 2002, 10(3), 443-455. (Pubitemid 35284166)
76. De Luca, A.; De Falco, M.; Severino, A.; Campioni, M.; Santini, D.; Baldi, F.; Paggi, M. G.; Baldi, A. Distribution of the serine protease HtrA1 in normal human tissues. J. Histochem. Cytochem. 2003, 51(10), 1279-1284. (Pubitemid 37187579)
77. De Luca, A.; De Falco, M.; Fedele, V.; Cobellis, L.; Mastrogiacomo, A.; Laforgia, V.; Tuduce, I. L.; Campioni, M.; Giraldi, D.; Paggi, M. G.; Baldi, A. The serine protease HtrA1 is upregulated in the human placenta during pregnancy. J. Histochem. Cytochem. 2004, 52(7), 885-892. (Pubitemid 38857153)
78. Wu, G.; Chai, J.; Suber, T. L.; Wu, J. W.; Du, C.; Wang, X.; Shi, Y. Structural basis of IAP recognition by Smac/DIABLO. Nature 2000, 408(6815), 1008-1012 (Pubitemid 32101651)
79. Hegde, R.; Srinivasula, S. M.; Zhang, Z.; Wassell, R.; Mukattash, R.; Cilenti, L.; DuBois, G.; Lazebnik, Y.; Zervos, A. S.; Fernandes-Alnemri, T.; Alnemri, E. S. Identification of Omi/HtrA2 as a mitochondrial apoptotic serine protease that disrupts inhibitor of apoptosis protein-caspase interaction. J. Biol. Chem. 2002, 277(1), 432-438. (Pubitemid 34952076)
80. Martins, L. M.; Iaccarino, I.; Tenev, T.; Gschmeissner, S.; Totty, N. F.; Lemoine, N. R.; Savopoulos, J.; Gray, C. W.; Creasy, C. L.; Dingwall, C.; Downward, J. The serine protease Omi/HtrA2 regulates apoptosis by binding XIAP through a reaper-like motif. J. Biol. Chem. 2002, 277(1), 439-444. (Pubitemid 34952077)
81. van Loo, G.; van Gurp, M.; Depuydt, B.; Srinivasula, S. M.; Rodriguez, I.; Alnemri, E. S.; Gevaert, K.; Vandekerckhove, J.; Declercq, W.; Vandenabeele, P. The serine protease Omi/HtrA2 is released from mitochondria during apoptosis. Omi interacts with caspase-inhibitor XIAP and induces enhanced caspase activity. Cell Death Differ. 2002, 9(1), 20-26. (Pubitemid 34071990)
82. Bartke, T.; Pohl, C.; Pyrowolakis, G.; Jentsch, S. Dual role of BRUCE as an antiapoptotic IAP and a chimeric E2/E3 ubiquitin ligase. Mol. Cell. 2004, 14(6), 801-811. (Pubitemid 38780853)
83. Seong, Y. M.; Choi, J. Y.; Park, H. J.; Kim, K. J.; Ahn, S. G.; Seong G. H.; Kim, I. K.; Kang, S.; Rhim, H. Autocatalytic processing of HtrA2/Omi is essential for induction of caspase-dependent cell death through antagonizing XIAP. J. Biol. Chem. 2004, 279(36), 37588-37596. (Pubitemid 39195472)
84. Srinivasula, S. M.; Gupta, S.; Datta, P.; Zhang, Z.; Hegde, R.; Cheong, N.; Fernandes-Alnemri, T.; Alnemri, E. S. Inhibitor of apoptosis proteins are substrates for the mitochondrial serine protease Omi/HtrA2. J. Biol. Chem. 2003, 278(34), 31469-31472. (Pubitemid 37048322)
85. Suzuki, Y.; Takahashi-Niki, K.; Akagi, T.; Hashikawa, T.; Takahashi, R. Mitochondrial protease Omi/HtrA2 enhances caspase activation through multiple pathways. Cell Death Differ. 2004, 11(2), 208-216. (Pubitemid 38159645)
86. Yang, Q. H.; Church-Hajduk, R.; Ren, J.; Newton, M. L.; Du, C. Omi/HtrA2 catalytic cleavage of inhibitor of apoptosis (IAP) irreversibly inactivates IAPs and facilitates caspase activity in apoptosis. Genes Dev. 2003, 17(12), 1487-1496. (Pubitemid 36734706)
87. Park, H. J.; Seong, Y. M.; Choi, J. Y.; Kang, S.; Rhim, H. Alzheimer's disease-associated amyloid beta interacts with the human serine protease HtrA2/Omi. Neurosci. Lett. 2004, 357(1), 63-67. (Pubitemid 38186671)
88. Liu, M. L.; Liu, M. J.; Kim, J. M.; Kim, H. J.; Kim, J. H.; Hong, S. T. HtrA2 interacts with A beta peptide but does not directly alter its production or degradation. Mol. Cells 2005, 20(1), 83-89.
89. Gupta, S.; Singh, R.; Datta, P.; Zhang, Z.; Orr, C.; Lu, Z.; Dubois, G.; Zervos, A. S.; Meisler, M. H.; Srinivasula, S. M.; Fernandes-Alnemri, T.; Alnemri, E. S. The C-terminal tail of presenilin regulates Omi/HtrA2 protease activity. J. Biol. Chem. 2004, 279(44), 45844-45854. (Pubitemid 39491577)
90. Park, H. J.; Kim, S. S.; Seong, Y. M.; Kim, K. H.; Goo, H. G.; Yoon, E. J.; Min do, S.; Kang, S.; Rhim, H. Beta-amyloid precursor protein is a direct cleavage target of HtrA2 serine protease. Implications for the physiological function of HtrA2 in the mitochondria. J. Biol. Chem. 2006, 281(45), 34277-34287. (Pubitemid 46036636)
91. Huttunen, H. J.; Guénette, S. Y.; Peach, C.; Greco, C.; Xia, W.; Kim, D. Y.; Barren, C.; Tanzi, R. E.; Kovacs, D. M. HtrA2 regulates beta-amyloid precursor protein (APP) metabolism through endoplasmic reticulum-associated degradation. J. Biol. Chem. 2007, 282(38), 28285-28295. (Pubitemid 47529538)
92. Nie, G. Y.; Li, Y.; Minoura, H.; Batten, L.; Ooi, G. T.; Findlay, J. K.; Salamonsen, L. A. A novel serine protease of the mammalian HtrA family is up-regulated in mouse uterus coinciding with placentation. Mol. Hum. Reprod. 2003, 9(5), 279-290. (Pubitemid 36748831)
93. Rhodes, D. R.; Kalyana-Sundaram, S.; Mahavisno, V.; Varambally, R.; Yu, J.; Briggs, B. B.; Barrette, T. R.; Anstet, M. J.; Kincead-Beal, C.; Kulkarni, P.; Varambally, S.; Ghosh, D.; Chinnaiyan, A. M. Oncomine 3.0: genes, pathways, and networks in a collection of 18,000 cancer gene expression profiles. Neoplasia 2007, 9(2), 166-180. (Pubitemid 46318375)
94. Chien, J.; Staub, J.; Hu, S. I.; Erickson-Johnson, M. R.; Couch, F. J.; Smith, D. I.; Crowl, R. M.; Kaufmann, S. H.; Shridhar, V. A candidate tumor suppressor HtrA1 is downregulated in ovarian cancer. Oncogene 2004, 23(8), 1636-1644. (Pubitemid 38406528)
95. Baldi, A.; De Luca, A.; Morini, M.; Battista, T.; Felsani, A.; Baldi, F.; Catricalà, C.; Amantea, A.; Noonan, D. M.; Albini, A.; Natali, P. G.; Lombardi, D.; Paggi, M. G. The HtrA1 serine protease is down-regulated during human melanoma progression and represses growth of metastatic melanoma cells. Oncogene 2002, 21(43), 6684-6688. (Pubitemid 35177048)
96. Esposito, V.; Campioni, M.; De Luca, A; Spugnini, E. P.; Baldi, F.; Cassandro, R.; Mancini, A.; Vincenzi, B.; Groeger, A.; Caputi, M.; Baldi, A. Analysis of HtrA1 serine protease expression in human lung cancer. Anti Cancer Res. 2006, 26(5A), 3455-3459. (Pubitemid 44701522)
97. Baldi, A., Mottolese, M.; Vincenzi, B.; Campioni, M.; Mellone, P.; Di Marino, M.; Di Crescenzo, V. G.; Visca, P.; Menegozzo, S.; Spugnini, E. P.; Citro, G.; Ceribelli, A.; Mirri, A.; Chien, J.; Shridhar, V.; Ehrmann, M.; Santini, M.; Facciolo, F. The serine protease HTRA1 is a novel prognostic factor for human mesothelioma. Pharmacogenomics 2008, 9(8), 1069-1077.
98. Kotliarov, Y.; Steed, M. E.; Christopher, N.; Walling, J.; Su, Q.; Center, A.; Heiss, J.; Rosenblum, M.; Mikkelsen, T.; Zenklusen, J. C.; Fine, H. A. High-resolution global genomic survey of 178 gliomas reveals novel regions of copy number alteration and allelic imbalances. Cancer Res. 2006, 66(19), 9428-9436. (Pubitemid 44623639)
99. Pomeroy, S. L.; Tamayo, P; Gaasenbeek, M.; Sturla, L. M.; Angelo, M.; McLaughlin, M. E.; Kim, J. Y.; Goumnerova, L. C.; Black, P. M.; Lau, C.; Allen, J. C.; Zagzag, D.; Olson, J. M.; Curran, T.; Wetmore, C.; Biegel, J. A.; Poggio, T.; Mukherjee, S.; Rifkin, R.; Califano, A.; Stolovitzky, G.; Louis, D. N.; Mesirov, J. P.; Lander, E. S.; Golub, T. R. Prediction of central nervous system embryonal tumour outcome based on gene expression. Nature 2002, 415(6870), 436-442. (Pubitemid 34100955)
100. Lee, J.; Kotliarova. S; Kotliarov, Y.; Li, A.; Su, Q.; Donin, N. M.; Pastorino, S.; Purow, B. W.; Christopher, N.; Zhang, W.; Park, J. K.; Fine, H. A. Tumor stem cells derived from glioblastomas cultured in bFGF and EGF more closely mirror the phenotype and genotype of primary tumors than do serum-cultured cell lines. Cancer Cell. 2006, 9(5), 391-403. (Pubitemid 43668737)
101. Hendrix, N. D.; Wu, R.; Kuick, R.; Schwartz, D. R.; Fearon, E. R.; Cho, K. R. Fibroblast growth factor 9 has oncogenic activity and is a downstream target of Wnt signaling in ovarian endometrioid adenocarcinomas. Cancer Res. 2006, 66(3), 1354-1362. (Pubitemid 43259914)
102. Welsh, J. B.; Zarrinkar, P. P.; Sapinoso, L. M.; Kern, S. G.; Behling, C. A.; Monk, B. J.; Lockhart, D. J.; Burger, R. A.; Hampton, G. M. Analysis of gene expression profiles in normal and neoplastic ovarian tissue samples identifies candidate molecular markers of epithelial ovarian cancer. Proc. Natl. Acad. Sci. USA 2001, 98(3), 1176-1181. (Pubitemid 32121206)
103. Lu, K. H.; Patterson, A. P.; Wang, L.; Marquez, R. T.; Atkinson, E. N.; Baggerly, K. A.; Ramoth, L. R.; Rosen, D. G.; Liu, J.; Hellstrom, I.; Smith, D.; Hartmann, L.; Fishman, D.; Berchuck, A.; Schmandt, R.; Whitaker, R.; Gershenson, D. M.; Mills, G. B.; Bast, R. C. Jr.; Selection of potential markers for epithelial ovarian cancer with gene expression arrays and recursive descent partition analysis. Clin. Cancer Res. 2004, 10(10), 3291-3300. (Pubitemid 38685433)
104. Adib, T. R.; Henderson, S.; Perrett, C.; Hewitt, D.; Bourmpoulia, D; Ledermann, J.; Boshoff, C. Predicting biomarkers for ovarian cancer using gene-expression microarrays. Br. J. Cancer 2004, 90(3), 686-692. (Pubitemid 38297211)
105. Ginos, M. A.; Page, G. P.; Michalowicz, B. S.; Patel, K. J.; Volker, S. E.; Pambuccian, S. E.; Ondrey, F. G.; Adams, G. L.; Gaffney, P. M. Identification of a gene expression signature associated with recurrent disease in squamous cell carcinoma of the head and neck. Cancer Res. 2004, 64(1), 55-63. (Pubitemid 38114082)
106. Talbot, S. G.; Estilo, C.; Maghami, E.; Sarkaria, I. S.; Pham, D. K.; O-charoenrat, P.; Socci, N. D.; Ngai, I.; Carlson, D.; Ghossein, R.; Viale, A.; Park, B. J.; Rusch, V. W.; Singh, B. Gene expression profiling allows distinction between primary and metastatic squamous cell carcinomas in the lung. Cancer Res. 2005, 65(8), 3063-3071. (Pubitemid 40524586)
107. Gordon, G. J., Jensen, R. V.; Hsiao, L. L.; Gullans, S. R.; Blumenstock, J. E.; Ramaswamy, S.; Richards, W. G.; Sugarbaker, D. J.; Bueno, R. Translation of microarray data into clinically relevant cancer diagnostic tests using gene expression ratios in lung cancer and mesothelioma. Cancer Res. 2002, 62(17), 4963-4967. (Pubitemid 34984420)
108. Farmer, P.; Bonnefoi, H.; Becette, V.; Tubiana-Hulin, M.; Fumoleau, P.; Larsimont, D.; Macgrogan, G.; Bergh, J.; Cameron, D.; Goldstein, D.; Duss, S.; Nicoulaz, A. L.; Brisken, C.; Fiche, M.; Delorenzi, M.; Iggo, R. Identification of molecular apocrine breast tumours by microarray analysis. Oncogene 2005, 24(29), 4660-4671. (Pubitemid 41032603)
109. Wang, Y.; Klijn, J. G.; Zhang, Y.; Sieuwerts, A. M.; Look, M. P.; Yang, F.; Talantov, D.; Timmermans, M.; Meijer-van, Gelder, M. E.; Yu, J.; Jatkoe, T.; Berns, E. M.; Atkins, D.; Foekens, J. A. Gene-expression profiles to predict distant metastasis of lymphnode-negative primary breast cancer. Lancet 2005, 365(9460), 671-679. (Pubitemid 40260888)
110. Desmedt, C.; Piette, F.; Loi, S.; Wang ,Y; Lallemand ,F.; Haibe-Kains, B.; Viale, G.; Delorenzi, M.; Zhang, Y.; d'Assignies, M. S.; Bergh, J; Lidereau, R.; Ellis, P.; Harris, A. L.; Klijn, J. G.; Foekens, J. A.; Cardoso, F.; Piccart, M. J.; Buyse, M.; Sotiriou, C.; TRANSBIG Consortium. Strong time dependence of the 76-gene prognostic signature for node-negative breast cancer patients in the TRANSBIG multicenter independent validation series. Clin. Cancer Res. 2007, 13(11), 3207-3214.
111. van de Vijver, M. J.; He, Y. D.; van't Veer, L. J.; Dai, H.; Hart, A. A.; Voskuil, D. W.; Schreiber, G. J.; Peterse, J. L.; Roberts, C.; Marton, M. J.; Parrish, M.; Atsma, D.; Witteveen, A.; Glas, A.; Delahaye, L.; van der Velde, T.; Bartelink, H.; Rodenhuis, S.; Rutgers, E. T.; Friend, S. H.; Bernards, R. A gene-expression signature as a predictor of survival in breast cancer. N. Engl. J. Med. 2002, 347(25), 1999-2009.
112. Chin, K.; DeVries, S.; Fridlyand, J.; Spellman, P. T.; Roydasgupta, R.; Kuo, W. L.; Lapuk, A.; Neve, R. M.; Qian, Z.; Ryder, T.; Chen, F.; Feiler, H.; Tokuyasu, T.; Kingsley, C.; Dairkee, S.; Meng, Z.; Chew, K.; Pinkel, D.; Jain, A.; Ljung, B. M.; Esserman, L.; Albertson, D. G.; Waldman, F. M.; Gray, J. W. Genomic and transcriptional aberrations linked to breast cancer pathophysiologies. Cancer Cell 2006, 10(6), 529-541. (Pubitemid 44854748)
113. van 't Veer, L. J.; Dai, H.; van de Vijver, M. J.; He, Y. D.; Hart, A. A.; Mao, M.; Peterse, H. L.; van der Kooy, K.; Marton, M. J.; Witteveen, A. T.; Schreiber, G. J.; Kerkhoven, R. M.; Roberts, C.; Linsley, P. S.; Bernards, R.; Friend, S. H. Gene expression profiling predicts clinical outcome of breast cancer. Nature 2002, 415(6871), 530-536.
114. Ivshina, A. V.; George, J.; Senko, O.; Mow, B.; Putti, T. C.; Smeds, J.; Lindahl, T.; Pawitan, Y.; Hall, P.; Nordgren, H.; Wong, J. E.; Liu, E. T.; Bergh, J.; Kuznetsov, V. A.; Miller, L. D. Genetic reclassification of histologic grade delineates new clinical subtypes of breast cancer. Cancer Res. 2006, 66(21), 10292-10301. (Pubitemid 44799747)
115. Miller, L. D.; Smeds, J.; George, J.; Vega, V. B.; Vergara, L.; Ploner, A.; Pawitan, Y.; Hall, P.; Klaar, S.; Liu, E. T.; Bergh, J. An expression signature for p53 status in human breast cancer predicts mutation status, transcriptional effects, and patient survival. Proc. Natl. Acad. Sci. USA 2005, 102(38), 13550-13555. (Pubitemid 41420886)
116. Sotiriou, C.; Wirapati. P.; Loi, S.; Harris, A.; Fox, S.; Smeds, J.; Nordgren, H.; Farmer, P.; Praz, V.; Haibe-Kains, B.; Desmedt, C.; Larsimont, D.; Cardoso, F.; Peterse, H.; Nuyten, D.; Buyse, M.; Van de Vijver, M. J.; Bergh, J.; Piccart, M.; Delorenzi, M. Gene expression profiling in breast cancer: understanding the molecular basis of histologic grade to improve prognosis. J. Natl. Cancer Inst. 2006, 98(4), 262-272. (Pubitemid 43264710)
117. Raetz, E. A.; Perkins, S. L.; Bhojwani, D.; Smock, K.; Philip, M.; Carroll, W. L.; Min, D. J. Gene expression profiling reveals intrinsic differences between T-cell acute lymphoblastic leukemia and Tcell lymphoblastic lymphoma. Pediatr. Blood Cancer 2006, 47(2), 130-140. (Pubitemid 44025244)
118. Mullighan, C. G., Goorha, S.; Radtke, I.; Miller, C. B.; Coustan-Smith, E; Dalton, J. D.; Girtman, K.; Mathew, S.; Ma, J.; Pounds, S. B.; Su, X.; Pui, C. H.; Relling, M. V.; Evans, W. E.; Shurtleff, S. A.; Downing, J. R. Genome-wide analysis of genetic alterations in acute lymphoblastic leukaemia. Nature 2007, 446(7137), 758-764. (Pubitemid 46582031)
119. Welsh, J. B.; Sapinoso, L. M.; Su, A. I.; Kern, S. G.; Wang-Rodriguez, J.; Moskaluk, C. A.; Frierson, H. F. Jr.; Hampton, G. M. Analysis of gene expression identifies candidate markers and pharmacological targets in prostate cancer. Cancer Res. 2001, 61(16), 5974-5978. (Pubitemid 32762523)
120. Holzbeierlein, J.; Lal, P.; LaTulippe, E.; Smith, A.; Satagopan, J.; Zhang, L.; Ryan, C.; Smith, S.; Scher, H.; Scardino, P.; Reuter, V.; Gerald, W. L. Gene expression analysis of human prostate carcinoma during hormonal therapy identifies androgen-responsive genes and mechanisms of therapy resistance. Am. J. Pathol. 2004, 164(1), 217-227. (Pubitemid 38364606)
121. Yu, Y. P.; Landsittel, D.; Jing, L.; Nelson, J.; Ren, B.; Liu, L.; McDonald, C.; Thomas, R.; Dhir, R.; Finkelstein, S.; Michalopoulos, G.; Becich, M.; Luo, J. H. Gene expression alterations in prostate cancer predicting tumor aggression and preceding development of malignancy. J. Clin. Oncol. 2004, 22(14), 2790-2799. (Pubitemid 41079896)
122. Varambally, S.; Yu, J.; Laxman, B.; Rhodes, D. R.; Mehra, R.; Tomlins, S. A.; Shah, R. B.; Chandran, U.; Monzon, F. A.; Becich, M. J.; Wei, J. T.; Pienta, K. J.; Ghosh, D.; Rubin, M. A.; Chinnaiyan, A. M. Integrative genomic and proteomic analysis of prostate cancer reveals signatures of metastatic progression. Cancer Cell. 2005, 8(5), 393-406. (Pubitemid 41579834)
123. Segal, N. H., Pavlidis, P.; Noble, W. S.; Antonescu, C. R.; Viale, A.; Wesley, U. V.; Busam, K.; Gallardo, H.; De Santis, D.; Brennan, M. F.; Cordon-Cardo, C.; Wolchok, J. D.; Houghton, A. N. Classification of clear-cell sarcoma as a subtype of melanoma by genomic profiling. J. Clin. Oncol. 2003, 21(9), 1775-1781. (Pubitemid 46638591)
124. Talantov, D.; Mazumder, A.; Yu, J. X.; Briggs, T.; Jiang, Y.; Backus, J.; Atkins, D.; Wang, Y. Novel genes associated with malignant melanoma but not benign melanocytic lesions. Clin. Cancer Res. 2005, 11(20), 7234-7242. (Pubitemid 41507680)
125. Tschentscher, F.; Hüsing, J.; Hölter, T.; Kruse, E.; Dresen, I. G.; Jöckel, K. H.; Anastassiou, G.; Schilling, H.; Bornfeld, N.; Horsthemke, B.; Lohmann, D. R.; Zeschnigk, M. Tumor classification based on gene expression profiling shows that uveal melanomas with and without monosomy 3 represent two distinct entities. Cancer Res. 2003, 63(10), 2578-2584. (Pubitemid 36608917)
126. Cutcliffe, C.; Kersey, D.; Huang, C. C.; Zeng, Y.; Walterhouse, D.; Perlman, E. J. Renal Tumor Committee of the Children's Oncology Group. Clear cell sarcoma of the kidney: up-regulation of neural markers with activation of the sonic hedgehog and Akt pathways. Clin. Cancer Res. 2005, 11(22), 7986-7994.
127. Sanchez-Carbayo, M.; Socci, N. D.; Lozano, J.; Saint, F.; Cordon-Cardo,
128. Stearman, R. S.; Dwyer-Nield, L.; Zerbe, L.; Blaine, S. A.; Chan, Z.; Bunn, P. A. Jr.; Johnson, G. L.; Hirsch, F. R.; Merrick, D. T.; Franklin, W. A.; Baron, A. E.; Keith, R. L.; Nemenoff, R. A.; Malkinson, A. M.; Geraci, M. W. Analysis of orthologous gene expression between human pulmonary adenocarcinoma and a carcinogen-induced murine model. Am. J. Pathol. 2005, 167(6), 1763-1775. (Pubitemid 41713326)
129. Bhattacharjee, A., Richards, W. G.; Staunton, J.; Li, C.; Monti, S.; Vasa, P.; Ladd, C.; Beheshti, J.; Bueno, R.; Gillette, M.; Loda, M.; Weber, G.; Mark, E. J.; Lander, E. S.; Wong, W.; Johnson, B. E.; Golub, T. R.; Sugarbaker, D. J.; Meyerson, M. Classification of human lung carcinomas by mRNA expression profiling reveals distinct adenocarcinoma subclasses. Proc. Natl. Acad. Sci. USA 2001, 98(24), 13790-13795. (Pubitemid 33115977)
130. Dyrskjot, L.; Kruhøffer, M.; Thykjaer, T.; Marcussen, N.; Jensen, J. L.; Møller, K.; Ørntoft, T. F. Gene expression in the urinary bladder: a common carcinoma in situ gene expression signature exists disregarding histopathological classification. Cancer Res. 2004, 64(11), 4040-4048. (Pubitemid 38697320)
131. Stransky, N.; Vallot, C.; Reyal, F.; Bernard-Pierrot, I.; de Medina, S. G.; Segraves, R.; de Rycke, Y.; Elvin, P.; Cassidy, A.; Spraggon, C.; Graham, A.; Southgate, J.; Asselain, B.; Allory, Y.; Abbou, C. C.; Albertson, D. G.; Thiery, J. P.; Chopin, D. K.; Pinkel, D.; Radvanyi, F. Regional copy number-independent deregulation of transcription in cancer. Nat. Genet. 2006, 38(12), 1386-1396. (Pubitemid 44837560)
132. Sun, L.; Hui, A. M.; Su, Q.; Vortmeyer, A.; Kotliarov, Y.; Pastorino, S.; Passaniti, A.; Menon, J.; Walling, J.; Bailey, R.; Rosenblum, M.; Mikkelsen, T.; Fine, H. A. Neuronal and glioma-derived stem cell factor induces angiogenesis within the brain. Cancer Cell 2006, 9(4), 287-300.
133. Haslinger, C.; Schweifer, N.; Stilgenbauer, S.; Döhner, H.; Lichter, P.; Kraut, N.; Stratowa, C.; Abseher, R. Microarray gene expression profiling of B-cell chronic lymphocytic leukemia subgroups defined by genomic aberrations and VH mutation status. J. Clin. Oncol. 2004, 22(19), 3937-3949. (Pubitemid 41079876)
134. Andersson, A.; Ritz, C.; Lindgren, D.; Edén, P.; Lassen, C.; Heldrup, J.; Olofsson, T.; Råde, J.; Fontes, M.; Porwit-Macdonald, A.; Behrendtz, M.; Höglund, M.; Johansson, B.; Fioretos, T. Microarray-based classification of a consecutive series of 121 childhood acute leukemias: prediction of leukemic and genetic subtype as well as of minimal residual disease status. Leukemia 2007, 21(6), 1198-1203. (Pubitemid 46831808)
135. Boni, J. P.; Leister, C.; Bender, G.; Fitzpatrick, V.; Twine, N.; Stover, J.; Dorner, A.; Immermann, F.; Burczynski, M. E. Population pharmacokinetics of CCI-779: correlations to safety and pharmacogenomic responses in patients with advanced renal cancer. Clin. Pharmacol. Ther. 2005, 77(1), 76-89. (Pubitemid 40075391)
136. Bild, A. H.; Yao, G.; Chang, J. T.; Wang, Q.; Potti, A.; Chasse, D.; Joshi, M. B.; Harpole, D.; Lancaster, J. M.; Berchuck, A.; Olson, J. A. Jr.; Marks, J. R.; Dressman, H. K.; West, M.; Nevins, J. R. Oncogenic pathway signatures in human cancers as a guide to targeted therapies. Nature 2006, 439(7074), 353-357. (Pubitemid 43128862)
137. Watanabe, T.; Kobunai, T.; Toda, E.; Yamamoto, Y.; Kanazawa, T.; Kazama, Y.; Tanaka, J.; Tanaka, T.; Konishi, T.; Okayama, Y.; Sugimoto, Y.; Oka, T.; Sasaki, S.; Muto, T.; Nagawa, H. Distal colorectal cancers with microsatellite instability (MSI) display distinct gene expression profiles that are different from proximal MSI cancers. Cancer Res. 2006, 66(20), 9804-9808. (Pubitemid 44672030)
138. Sorlie, T.; Perou, C. M.; Tibshirani, R.; Aas, T.; Geisler, S.; Johnsen, H.; Hastie, T.; Eisen, M. B.; van de Rijn, M.; Jeffrey, S. S.; Thorsen, T.; Quist, H.; Matese, J. C.; Brown, P. O.; Botstein, D.; Eystein Lønning, P.; Børresen-Dale, A. L. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc. Natl. Acad. Sci. USA 2001, 98(19), 10869-10874. (Pubitemid 32878711)
139. Sorlie, T.; Tibshirani, R.; Parker, J.; Hastie, T.; Marron, J. S.; Nobel, A.; Deng, S.; Johnsen, H.; Pesich, R.; Geisler, S.; Demeter, J.; Perou, C. M.; Lønning, P. E.; Brown, P. O.; Børresen-Dale, A. L.; Botstein, D. Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc. Natl. Acad. Sci. USA 2003, 100(14), 8418-8423. (Pubitemid 36842560)
140. Hummel, M., Bentink, S.; Berger, H.; Klapper, W.; Wessendorf, S.; Barth, T. F.; Bernd, H. W.; Cogliatti, S. B.; Dierlamm, J.; Feller, A. C.; Hansmann, M. L.; Haralambieva, E.; Harder, L.; Hasenclever, D.; Kühn, M.; Lenze, D.; Lichter, P.; Martin-Subero, J. I.; Möller, P.; Müller-Hermelink, H. K.; Ott, G.; Parwaresch, R. M.; Pott, C.; Rosenwald, A.; Loeffler, M.; Trümper, L.; Stein, H.; Siebert, R. Molecular Mechanisms in Malignant Lymphomas Network Project of the Deutsche Krebshilfe. A biologic definition of Burkitt's lymphoma from transcriptional and genomic profiling. N. Engl. J. Med. 2006, 354(23), 2419-2430.
141. Dhanasekaran, S. M.; Barrette, T. R.; Ghosh, D.; Shah, R.; Varambally, S.; Kurachi, K.; Pienta, K. J.; Rubin, M. A.; Chinnaiyan, A. M. Delineation of prognostic biomarkers in prostate cancer. Nature 2001, 412(6849), 822-826. (Pubitemid 32801464)
142. Korkola, J. E.; Houldsworth, J.; Chadalavada, R. S.; Olshen, A. B.; Dobrzynski, D.; Reuter, V. E.; Bosl, G. J.; Chaganti, R. S. Down-regulation of stem cell genes, including those in a 200-kb gene cluster at 12p13.31, is associated with in vivo differentiation of human male germ cell tumors. Cancer Res. 2006, 66(2), 820-827. (Pubitemid 43165947)
143. Hao, Y.; Triadafilopoulos, G.; Sahbaie, P.; Young, H. S.; Omary, M. B.; Lowe, A. W. Gene expression profiling reveals stromal genes expressed in common between Barrett's esophagus and adenocarcinoma. Gastroenterology 2006, 131(3), 925-933. (Pubitemid 44307058)
144. Iacobuzio-Donahue, C. A.; Maitra, A.; Olsen, M.; Lowe, A. W.; van Heek, N. T.; Rosty, C.; Walter, K.; Sato, N.; Parker, A.; Ashfaq, R.; Jaffee, E.; Ryu, B.; Jones, J.; Eshleman, J. R.; Yeo, C. J.; Cameron, J. L.; Kern, S. E.; Hruban, R. H.; Brown, P. O.; Goggins, M. Exploration of global gene expression patterns in pancreatic adenocarcinoma using cDNA microarrays. Am. J. Pathol. 2003, 162(4), 1151-1162. (Pubitemid 36350660)
145. Ross, M. E.; Zhou, X.; Song, G.; Shurtleff, S. A.; Girtman, K.; Williams, W. K.; Liu, H. C.; Mahfouz, R.; Raimondi, S. C.; Lenny, N.; Patel, A.; Downing, J. R. Classification of pediatric acute lymphoblastic leukemia by gene expression profiling. Blood 2003, 102(8), 2951-2959. (Pubitemid 37248870)
146. Fine, B. M.; Stanulla, M.; Schrappe, M.; Ho, M.; Viehmann, S.; Harbott, J.; Boxer, L. M. Gene expression patterns associated with recurrent chromosomal translocations in acute lymphoblastic leukemia. Blood 2004, 103(3), 1043-1049. (Pubitemid 38129570)
147. Heuser, M.; Wingen, L. U.; Steinemann, D.; Cario, G.; von Neuhoff, N.; Tauscher, M.; Bullinger, L.; Krauter, J.; Heil, G.; Döhner, H.; Schlegelberger, B.; Ganser, A. Gene-expression profiles and their association with drug resistance in adult acute myeloid leukemia. Haematologic 2005, 90(11), 1484-1492. (Pubitemid 41658761)
148. Schmidt, S.; Rainer, J.; Riml, S.; Ploner, C.; Jesacher, S.; Achmüller, C.; Presul, E.; Skvortsov, S.; Crazzolara, R.; Fiegl, M.; Raivio, T.; Jänne, O. A.; Geley, S.; Meister, B.; Kofler, R. Identification of glucocorticoid-response genes in children with acute lymphoblastic leukemia. Blood 2006, 107(5), 2061-2069. (Pubitemid 43292367)
149. Maser, R. S.; Choudhury, B.; Campbell, P. J.; Feng, B.; Wong K. K.; Protopopov, A.; O'Neil, J.; Gutierrez, A.; Ivanova, E.; Perna, I.; Wiedemeyer, R; Kabbara, O.; Nogueira, C.; Histen, G.; Aster, J.; Mansour, M.; Duke, V.; Foroni, L.; Fielding, A. K.; Goldstone, A. H.; Rowe, J. M.; Wang, Y. A.; Look, A. T.; Stratton, M. R.; Chin, L.; Futreal, P. A.; DePinho, R. A. Chromosomally unstable mouse tumours have genomic alterations similar to diverse human cancers. Nature 2007, 447(7147), 966-971. (Pubitemid 46975753)
150. Richardson, A. L.; Wang, Z. C.; De Nicolo, A; Lu, X.; Brown, M.; Miron, A.; Liao, X.; Iglehart, J. D.; Livingston, D. M.; Ganesan, S. X chromosomal abnormalities in basal-like human breast cancer. Cancer Cell. 2006, 9(2), 121-132. (Pubitemid 43202662)
151. Suen, D. F.; Norris, K. L.; Youle, R. J. Mitochondrial dynamics and apoptosis. Genes. Dev. 2008, 22(12), 1577-1590. (Pubitemid 351846838)
152. Bartling, B.; Lewensohn, R.; Zhivotovsky, B. Endogenously released Smac is insufficient to mediate cell death of human lung carcinoma in response to etoposide. Exp. Cell Res. 2004, 298(1), 83-95. (Pubitemid 38887309)
153. Folgueira, M. A.; Carraro, D. M.; Brentani, H.; Patrão, D. F.; Barbosa, E. M.; Netto, M. M.; Caldeira, J. R.; Katayama, M. L.; Soares, F. A.; Oliveira, C. T.; Reis, L. F.; Kaiano, J. H.; Camargo, L. P.; Vêncio, R. Z.; Snitcovsky, I. M.; Makdissi, F. B.; Silva, P. J.; Góes, J. C.; Brentani, M. M. Gene expression profile associated with response to doxorubicin-based therapy in breast cancer. Clin. Cancer Res. 2005, 11(20), 7434-7443. (Pubitemid 41507704)
154. Bovenschen, N.; de Koning, P. J.; Quadir, R.; Broekhuizen, R.; Damen, J. M.; Froelich, C. J.; Slijper, M.; Kummer, J. A. NK cell protease granzyme M targets alpha-tubulin and disorganizes the microtubule network. J. Immunol. 2008, 180, 8184-8191.
155. Martinvalet, D.; Dykxhoorn, D. M.; Ferrini, R.; Lieberman, J. Granzyme A cleaves a mitochondrial complex I protein to initiate caspase-independent cell death. Cell. 2008, 133(4), 681-692. (Pubitemid 351636303)
156. Balch, C.; Huang, T. H.; Brown, R.; Nephew, K. P. The epigenetics of ovarian cancer drug resistance and resensitization. Am. J. Obstet. Gynecol. 2004. 191(5), 1552-1572. (Pubitemid 39491180)
157. Schneider-Stock, R.; Ocker, M. Epigenetic therapy in cancer: molecular background and clinical development of histone deacetylase and DNA methyltransferase inhibitors. Drugs 2007, 10(8), 557-561. (Pubitemid 47186508)
158. Martins, L. M.; Turk, B. E.; Cowling, V.; Borg, A.; Jarrell, E. T.; Cantley, L. C.; Downward, J. Binding specificity and regulation of the serine protease and PDZ domains of HtrA2/Omi. J. Biol. Chem. 2003, 278(49), 49417-49427.